RVL Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
RVL Pharmaceuticals's earnings have been declining at an average annual rate of -3.4%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 5.6% per year.
Key information
-3.4%
Earnings growth rate
17.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 5.6% |
| Return on equity | -418.1% |
| Net Margin | -184.9% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
RVL Pharmaceuticals plc (NASDAQ:RVLP) Analysts Just Cut Their EPS Forecasts Substantially
Aug 16
Analysts Just Made A Major Revision To Their RVL Pharmaceuticals plc (NASDAQ:RVLP) Revenue Forecasts
May 13RVL Pharmaceuticals plc (NASDAQ:RVLP) Doing What It Can To Lift Shares
May 12RVL Pharmaceuticals (NASDAQ:RVLP) Is Making Moderate Use Of Debt
Apr 20Is RVL Pharmaceuticals (NASDAQ:RVLP) Using Debt Sensibly?
Jan 05RVL Pharmaceuticals sees Q3 net sales of UPNEEQ for eye treatment about $10M
Oct 18RVL Pharmaceuticals: Chapter 2 - A Developing Quandary
Sep 22RVL Pharma in pact with Revision Skincare to broaden access to products
Aug 30GAAP EPS of -$0.14 beats by $0.07, revenue of $8.45M misses by $0.07M
Aug 11RVL Pharma posts preliminary 42% sales growth for eye treatment
Jul 07RVL Pharmaceuticals (NASDAQ:RVLP) Is Carrying A Fair Bit Of Debt
Jul 04RVL Pharmaceuticals: Chapter 1 Gives A Mixed Picture
Jun 15New Forecasts: Here's What Analysts Think The Future Holds For RVL Pharmaceuticals plc (NASDAQ:RVLP)
Apr 01RVL Pharmaceuticals: A Makeover For An Ugly Duckling
Mar 30Osmotica: A Different Breed Of Cat
Dec 14Osmotica Pharmaceuticals (NASDAQ:OSMT) Takes On Some Risk With Its Use Of Debt
Aug 20Osmotica: Paring Down, Focusing On UPNEEQ
Jul 16Revenue & Expenses Breakdown
How RVL Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 37 | -68 | 67 | 3 |
| 31 Mar 23 | 37 | -56 | 71 | 4 |
| 31 Dec 22 | 50 | -52 | 79 | 4 |
| 30 Sep 22 | 43 | -53 | 85 | 4 |
| 30 Jun 22 | 35 | -66 | 93 | 5 |
| 31 Mar 22 | 38 | -76 | 91 | 4 |
| 31 Dec 21 | 18 | -83 | 84 | 6 |
| 30 Sep 21 | 16 | -115 | 81 | 9 |
| 30 Jun 21 | 40 | -86 | 74 | 9 |
| 31 Mar 21 | 28 | -82 | 72 | 11 |
| 31 Dec 20 | 28 | -89 | 73 | 13 |
| 30 Sep 20 | 87 | -64 | 75 | 18 |
| 30 Jun 20 | 126 | -178 | 78 | 24 |
| 31 Mar 20 | 183 | -285 | 90 | 27 |
| 31 Dec 19 | 240 | -271 | 93 | 32 |
| 30 Sep 19 | 246 | -351 | 95 | 38 |
| 30 Jun 19 | 247 | -243 | 88 | 40 |
| 31 Mar 19 | 261 | -112 | 79 | 43 |
| 31 Dec 18 | 264 | -110 | 74 | 43 |
| 30 Sep 18 | 274 | -1 | 67 | 53 |
| 30 Jun 18 | 262 | -10 | 63 | 50 |
| 31 Mar 18 | 248 | -31 | 60 | 47 |
| 31 Dec 17 | 246 | -41 | 57 | 42 |
| 31 Dec 16 | 218 | -42 | 63 | 29 |
Quality Earnings: RVLP.Q is currently unprofitable.
Growing Profit Margin: RVLP.Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if RVLP.Q's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare RVLP.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RVLP.Q is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: RVLP.Q has a negative Return on Equity (-418.14%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 22:52 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
RVL Pharmaceuticals plc is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Louise Chen | Cantor Fitzgerald & Co. |
| David Steinberg | Jefferies LLC |
| Glen Santangelo | Jefferies LLC |